Semla TP, Beizer JL, Higbee MD
1 2 Assistant Professor of Medicine, University of Chicago School of Medicine, Center for Liver Diseases, Chicago, IL 2 This summary reviews Sodhi M, Rezaeianzadeh R, Kezouh A, Etminan M
Retatrutide is the first triple-hormone candidate to reach late-stage obesity trials, and based on its Phase 2 results, it is widely viewed inside the pharmaceutical industry as the molecule most likely to set the next benchmark for what an obesity drug can deliver.[1] The TRIUMPH Phase 3 Program Retatrutide is now being tested in a Phase 3 program Eli Lilly calls TRIUMPH .[4] Phase 3 trials are the larger, longer studies the FDA generally requires before approving a new drug
Gold nanoparticles in diagnosis and treatment of alzheimers disease
"The Mediterranean Diet and Cardiovascular Health"